Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK

Nature Immunology

Volumn 9, Issue 12, 2008, Pages 1371-1378

  Zarnegar, Brian J ^a   Wang, Yaya ^a   Mahoney, Douglas J ^a   Dempsey, Paul W ^a   Cheung, Herman H ^b   He, Jeannie ^a   Shiba, Travis ^a   Yang, Xiaolu ^c   Yeh, Wen Chen ^d   Mak, Tak W ^d   Korneluk, Robert G ^b   Cheng, Genhong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN INDUCING KINASE; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; INHIBITOR OF APOPTOSIS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME DEGRADATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INHIBITION KINETICS; LETHALITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REGULATORY MECHANISM; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; ENZYME ACTIVATION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; NF-KAPPA B; RNA, SMALL INTERFERING; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3; TRANSFECTION;

EID: 56349164239     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1676     Document Type: Article

References (43)

1. Baeuerle, P.A. & Baltimore, D. NF-κB: Ten years after. Cell 87 13-20 (1996).
2. Iotsova, V. et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3, 1285-1289 (1997).
3. Kopp, E.B. & Ghosh, S. NF-κB and rel proteins in innate immunity. Adv. Immunol. 58, 1-27 (1995).
4. Bonizzi, G. & Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288 (2004).
5. Zandi, E. & Karin, M. Bridging the gap: Composition, regulation, and physiological function of the IκB kinase complex. Mol. Cell. Biol. 19, 4547-4551 (1999).
6. Coope, H.J. et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 21, 5375-5385 (2002).
7. Claudio, E., Brown, K., Park, S., Wang, H. & Siebenlist, U. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat. Immunol. 3, 958-965 (2002).
8. Dejardin, E. The alternative NF-κB pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochem. Pharmacol. 72, 1161-1179 (2006).
9. Matsushima, A. et al. Essential role of nuclear factor (NF)-κB-inducing kinase and inhibitor of κB (IκB) kinase a in NF-κB activation through lymphotoxin β receptor, but not through tumor necrosis factor receptor I. J. Exp. Med. 193, 631-636 (2001).
10. Shinkura, R. et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding NF-κB-inducing kinase. Nat. Genet. 22 74-77 (1999).
11. Yin, L. et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 291, 2162-2165 (2001).
12. Liao, G., Zhang, M., Harhaj, E.W. & Sun, S.C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 279, 26243-26250 (2004).
13. He, J.Q. et al. Rescue of TRAF3-null mice by p100 NF-κB deficiency. J. Exp. Med. 203, 2413-2418 (2006).
14. Grech, A.P. et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity 21, 629-642 (2004).
15. Annunziata, C.M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007).
16. Keats, J.J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007).
17. Bonizzi, G. et al. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23, 4202-4210 (2004).
18. Hunter, A.M., LaCasse, E.C. & Korneluk, R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12, 1543-1568 (2007).
19. Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681 (2007).
20. Vince, J.E. et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682-693 (2007).
21. Conte, D. et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol. Cell. Biol. 26, 699-708 (2006).
22. Conze, D.B. et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol. Cell. Biol. 25, 3348-3356 (2005).
23. Malinin, N.L., Boldin, M.P., Kovalenko, A.V. & Wallach, D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385, 540-544 (1997).
24. Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M. & Goeddel, D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83, 1243-1252 (1995).
25. He, L., Grammer, A.C., Wu, X. & Lipsky, P.E. TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-κB activation. J. Biol. Chem. 279, 55855-55865 (2004).
26. Dadgostar, H. & Cheng, G. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-κB activation but is dispensable for c-Jun N-terminal kinase signaling. J. Biol. Chem. 273, 24775-24780 (1998).
27. He, J.Q., Saha, S.K., Kang, J.R., Zarnegar, B. & Cheng, G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-κB pathway. J. Biol. Chem. 282, 3688-3694 (2007).
28. Saha, S.K. et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J. 25 3257-3263 (2006).
29. Brown, K.D., Hostager, B.S. & Bishop, G.A. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J. Exp. Med. 193, 943-954 (2001).
30. Brown, K.D., Hostager, B.S. & Bishop, G.A. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277, 19433-19438 (2002).
31. Moore, C.R. & Bishop, G.A. Differential regulation of CD40-mediated TNF receptor-associated factor degradation in B lymphocytes. J. Immunol. 175, 3780-3789 (2005).
32. Li, L. et al. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305, 1471-1474 (2004).
33. Ng, L.G. et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36, 1837-1846 (2006).
34. Zarnegar, B., Yamazaki, S., He, J.Q. & Cheng, G. Control of canonical NF-κB activation through the NIK-IKK complex pathway. Proc. Natl. Acad. Sci. USA 105, 3503-3508 (2008).
35. Beg, A.A., Sha, W.C., Bronson, R.T. & Baltimore, D. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev. 9, 2736-2746 (1995).
36. Gardam, S., Sierro, F., Basten, A., Mackay, F. & Brink, R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28, 391-401 (2008).
37. Matsuzawa, A. et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321, 663-668 (2008).
38. Gaither, A. et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling. Cancer Res. 67, 11493-11498 (2007).
39. Fischer, U., Janssen, K. & Schulze-Osthoff, K. Cutting-edge apoptosis-based therapeutics: A panacea for cancer? BioDrugs 21 273-297 (2007).
40. Xu, Y., Cheng, G. & Baltimore, D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 5, 407-415 (1996).
41. Sha, W.C., Liou, H.C., Tuomanen, E.I. & Baltimore, D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80, 321-330 (1995).
42. Holcik, M., Lefebvre, C.A., Hicks, K. & Korneluk, R.G. Cloning and characterization of the rat homologues of the Inhibitor of Apoptosis protein 1, 2, and 3 genes. BMC Genomics 3, 5 (2002).
43. Scherle, P.A., Dorshkind, K. & Witte, O.N. Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc. Natl. Acad. Sci. USA 87, 1908-1912 (1990).